Product Information:

BRIVAGET F.C. 25mg Tablets contain Brivaracetam as the active ingredient, a selective synaptic vesicle protein 2A (SV2A) ligand used as an adjunctive therapy in the treatment of partial-onset (focal) seizures. The film-coated (F.C.) formulation ensures stability, ease of swallowing, and consistent drug release. This lower-strength tablet is ideal for dose initiation, titration, or maintenance in sensitive patients, including those with hepatic impairment or requiring gradual therapy adjustment.

Uses of (BRIVAGET F.C. 25MG TABLETS):

1. Adjunctive treatment of partial-onset seizures in adults and adolescents aged 16 years and older.
2. Starting dose during therapy initiation or when down-titrating from higher strengths.
3. Maintenance therapy in patients stabilized on lower daily doses due to tolerability or comorbidities.

Key Benefits of (BRIVAGET F.C. 25MG TABLETS):

1. Enables precise dose titration for optimal seizure control
2. Low risk of pharmacokinetic drug interactions
3. Minimal sedation compared to older antiepileptics
4. Film-coated for improved palatability and gastric protection
5. Suitable for patients with liver dysfunction (with monitoring)

How To Use (BRIVAGET F.C. 25MG TABLETS):

Take exactly as prescribed—typically 25mg twice daily (morning and evening), with or without food. Swallow whole with water; do not crush, chew, or split. Maintain regular dosing intervals to sustain therapeutic blood levels. Do not stop abruptly, as this may increase seizure risk.

When Not to Use (BRIVAGET F.C. 25MG TABLETS):

Do not use if you have a known hypersensitivity to brivaracetam or any excipients in the tablet. Avoid initiating therapy in patients with severe hepatic impairment (Child-Pugh C) without medical supervision. Not indicated for children under 16, generalized epilepsy syndromes, or acute seizure emergencies.

Side Effects of (BRIVAGET F.C. 25MG TABLETS):

Common: Mild dizziness, fatigue, headache, or nausea—usually transient.

Rare but serious: Neuropsychiatric effects (e.g., anxiety, depression, irritability, suicidal thoughts), hypersensitivity reactions, or gait instability. Discontinue and consult a neurologist immediately if mood changes, hallucinations, or severe drowsiness occur.

Dosage: (BRIVAGET F.C. 25MG TABLETS):

Initial dose: 25mg twice daily, which may be increased weekly based on response and tolerability (e.g., to 50mg or 100mg twice daily).

In severe liver disease (Child-Pugh C): Maximum 25mg twice daily.

Always follow your neurologist’s dosing plan—do not self-adjust.

Who It’s For (BRIVAGET F.C. 25MG TABLETS):

Adults and adolescents (≥16 years) with focal epilepsy requiring low-dose initiation or maintenance therapy. Particularly suitable for elderly patients, those with comorbid liver conditions, or individuals sensitive to CNS side effects.

Warnings & Precautions:

Monitor closely for psychiatric symptoms—brivaracetam carries regulatory warnings for behavioral changes. Avoid alcohol. May impair driving until individual tolerance is established. Inform all healthcare providers about your epilepsy treatment. Use effective contraception if applicable, as data in pregnancy are limited.

Drug Interactions:

Rifampin may reduce brivaracetam plasma levels by ~30%. Additive CNS depression may occur with benzodiazepines, opioids, or sedatives. No significant interaction with most enzyme-inducing antiepileptic drugs. Always disclose all medications to your physician.

Additional Information:

Store below 30°C in a dry place, protected from light and moisture. Keep out of reach of children. Do not use after the expiration date printed on the blister pack. Available by prescription only in Pakistan.